Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

吉利德科学公司（Gilead Sciences）与LEO Pharma日前宣布达成战略合作伙伴关系，共同加速LEO Pharma的小分子口服STAT6项目的开发和商业化，旨在为炎症性疾病患者提供潜在治疗方案。

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

据吉利德此前新闻稿介绍，来那帕韦将为对现有疗法无有效应答的HIV感染者提供一种 每年仅需给药两次 的全新治疗方案。 来那帕韦具有300mg片剂和463.5mg/1.5mL注射剂两种剂型，其中 片剂被批准用于治疗起始时口服，取决于起始治疗选项，可在首剂长效来那帕韦注射之前或之时服用 。来那帕韦注射剂只需 每半年皮下注射一次。

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of ...